The HIV/AIDS Bureau (HAB) of HRSA has developed a series of clinical performance indicators for Ryan White HIV/AIDS Program-funded clinics as part of...
This multi-module curriculum is designed specifically for Medical Case Managers.
This guide is designed to assist health professionals in evaluating medical and dental considerations for treating people with HIV in the era of ART...
In response to newly identified, community-based HIV epidemics, the AETC NCRC has pulled together the following AETC Program and U.S. Centers for Dise...
This resource was developed to help healthcare agencies to train Community Health Workers (CHW) in order to integrate them into their HIV and other pr...
This training slide set covers aging-related concerns for people with HIV, including management of ART. Nearly half of people with HIV in the United S...
A basic overview of resistance testing and key aspects of medications used in treatment-experienced patients, review newer medications and their role...
Training slides provide a summary of data from the ATLAS and FLAIR studies and outlines a case for patient eligibility for long-acting injectable ART...
Training slides review potential ARV drug-drug interactions and identify resources for the evaluation of drug-drug interactions.
Training slides define the HIV-ASSIST decision-support tool for ART selection and describe how it's used in different clinical scenarios.
Training slides describe the safety and efficacy of the Dapivirine vaginal ring for sustained delivery of ARV drugs.
Case-based training slides review new antiretroviral treatment guidelines and medications.
Pre-Exposure Prophylaxis (PrEP) is recommended as an HIV prevention option for anyone with risks of acquiring HIV infection th...
Training slides provide an overview of the role of cabotegravir/rilpivirine injectables and other novel formulations in development for HIV treatment...
Training slides review the epidemiology of cardiovascular risk for people with HIV, and provide recommendations for mitigating the risks.
Case-based training slides review approaches and applications for second-line antiretroviral treatment regimens.
Comprehensive guidelines, including:
The continuum of engagement in HIV care is a framework for understanding the status of HIV care and treatment in the United States (Cheever 2007). An...
Immediate antiretroviral therapy (ART) means starting HIV treatment as soon as possible after the diagnosis of HIV infection, preferably on the first...
This digital glossary of HIV-related terms includes both lay and scientific descriptions and illustrations. Materials are in the public domain and may...
Training slides covering U.S. HHS treatment recommendations related to starting antiretroviral therapy (ART) in people with HIV infection. Topics incl...
Recommended management strategies for patients with HIV experiencing virologic failure (VF) while taking antiretroviral therapy (ART). The potential c...
Training slides review the genotype versus phenotype resistance testing process; the indications for a traditional genotype, an integrase genotype, an...
(Recorded 5/10/23)
This training reviews ways to implement a comprehensive initial visit for a person with newly diagnosed HIV including engaging in mu...
Below is a list of the newest pocket guides created by the MidAtlantic AETC. Descriptions for each resource can be found here:
Training slides review the Ending the HIV Epidemic initiative and identify threats to successfully ending the epidemic in the United States.
Training slides review data on long-acting antiretrovirals (LA ART), challenges for its use, and LA ART future directions.
Training slides review how neutralizing antibodies (bNAbs) develop in people with HIV, identify the potential future uses of bNAbs to prevent, treat a...
Training slides learning objectives include:
Training slides learning objectives include:
Training slides learning objectives include:
Training slides learning objectives include:
The National HIV Curriculum (NHC) provides free, up-to-date content for clinicians to learn about HIV diagnosis, treatment, and prevention. The 37 les...
(Recorded on 9/11/2023)
Dr. Gulick reviews the latest data on the optimal treatment of HIV with antiretroviral therapy and specifically ad...
Training slides provide updates and a recent systematic review of the risk of HIV transmission with low viral loads.
Training slides provide an overview of Cabenuva including the latest study findings, adverse effects, resistance, and special dosing considerations...
(Recorded on 08/09/2023)
Presenters provide significant findings and key updates from the 24th International AIDS Conference.
Kenn...
Developed in collaboration with the New England AETC and the Primary Care Development Corporation, these short videos portray the interwov...
Browse recorded mini-lectures on clinically relevant topics including HIV Biology and Basic Science, Guideline Updates, Antiretroviral Medications, an...
Access recorded trainings presented by the AETC National Clinician Consultation Center (NCCC) in partnership with Health Resources and Services Admini...
This Training Presentation lists strategies that reduce the risk of meningitis in people with HIV (PWH). Demonstrates how to recognize cli...
This training slide presents updated data long acting injectable (LAI) cabotegravir/rilpivirine for treatment. Differentiate monitoring st...
This Training Presentation will compare and contrast factors that affect medication adherence and apply a patient centered approach to ant...
The following slides describe the initial clinical management of people with a new diagnosis of HIV and preferred antiretroviral regimens.
Training slides list reasons to consider switching antiretroviral (ARV) therapy in virologically suppressed patient according to HHS guidelines, revie...
Training slides cover the basic concepts of antiretroviral therapy (ART) virologic failure and resistance testing.
Training slides review how to identify people who are appropriate for long-acting antiretroviral therapy (ART) for HIV treatment and prevention, appro...
These training slides guide providers in decision making on managing antiretroviral therapy and switching treatments, as well as discussions on preven...
These slides discuss relevant drug-drug interactions between common antidepressants and
antiretroviral drugs.
These training slides review current literature on the efficacy of long-acting anti-retroviral therapy, reasons to switch from oral to long-acting ART...
(Recorded on 03/11/2024)
This recorded webinar reviews the global epidemiology of pediatric HIV infection, describes efforts to prevent new child infec...
The National HIV Curriculum just launched a new podcast exploring practice-changing issues and updates in HIV diagnosis, management, and prevention vi...
(Recorded on 03/08/2024)
This recorded webinar discusses antiretroviral treatment (ART) for adults and adolescents. It also covers adherence to ART, ca...
These guidelines provide information on updates on antiretroviral therapy (ART) for people with HIV who are trying to conceive.
This publication reviews the potential benefits and rationale for rapid antiretroviral therapy (ART) starts; outlines potential pitfalls; and offers p...
These slides provide information on new antiretroviral therapies and cardiovascular disease treatment options for people with HIV.
These slides discuss the prevalence of osteoporosis in people with HIV (PWH) and the association of bone loss with antiretroviral therapy (ART) treatm...
These slides provide basic information on Dolutegravir-Rilpivirine, an antiretroviral therapy (ART) treatment, including key drug interactions and stu...
These slides provide an overview on preventive and treatment approaches directed to reducing health disparities among people with co-occurring HIV and...
This slide set includes case studies on patients with HIV presenting clinically with severe symptoms suspected of sepsis. The case studies allow for t...
These slides provide information on causes of creatinine elevation in people with HIV (PWH), workup of creatinine elevation, as well as the effects of...
These guideline slides provide information and recommendations on statin therapy as primary prevention for cardiovascular disease. Antiretroviral ther...
This presentation provides current guidelines for the use of antiretroviral therapy (ART) agents in adults and adolescents with HIV.
This recorded webinar, summarizes the pharmacologic action and effectiveness, as well as the appropriateness of HIV treatment with cabotegravir/rilpiv...
This presentation provides an overview on antiretroviral therapy (ART) recommendations, updates on immunizations, treatment of hepatitis C virus in pe...
Each year HRSA's HIV/AIDS Bureau sponsors a conference for Ryan White Program clinicians to learn about advances in care and treatment. The National A...
Speaker:
Aubrey Byron, BSN, RN, ACRN
Nurse/HIV Program Coordinator
Dartmouth Hitchcock Medical Center
Description:
This webinar will empower clinicians t...
The National Clinician Consultation Center Pharmacy contains the latest information on antiretroviral drugs and related resources, including NCCC-deve...
(Recorded on 07/07/2021)
This recorded 1-hour educational presentation discussed the successes of safe consumption site programs and the be...
(Recorded on 10/24/2024)
Stories engage people with lived experience, humanize provider training, and increase knowledge and sensitivity to...
This new online self-paced course: Introduction to Long-Acting Antiretroviral Therapy- Cabotegravir/Rilpivirine (CAB/RPV), is the first in a new serie...
This training session defines the latest in antiretroviral therapy with regard to when and what to start. It also discusses reasons for modifying ther...
The popular AETC Program app supports health care providers with point-of-care tools for HIV screening, prevention, and care.
(Recorded on 06/ 09/25)
Overview of HIV molecular surveillance in New Hampshire to explain what HIV molecular surveillance is and how indivi...
Training slides provide updates on tuberculosis in people with HIV including prevalence, prevention, and treatment.
Co-Author: Susa Coffey, MD; Medical Editor, AETC National Resource Center
An open-label study is evaluating the renal safety of elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild, or the "quad" pill) and cobicistat. For those patients with mild-to-moderate renal impairment (estimated glomerula...
The prevailing opinion among experts regarding the optimal CD4 T-cell count at which to start patients on antiretroviral therapy (ART) has shifted several times during the evolution of HIV treatment. These shifts reflect attempts to strike a balance between preventing HIV-associated illness and deat...
There was a pharmacokinetic study presented at the Conference on Retroviruses and Opportunistic Infections in Boston in February. It evaluated concentrations of tenofovir (TFV) and TFV-diphosphate (DP) in genital and rectal tissue. Also in anogenital fluid samples after administration of oral tenofo...
Researchers at the 2016 Conference on Retroviruses and Opportunistic Infections presented results from a randomized double-blind, double-dummy switch study of TAF/FTC. Over 660 patients with virologic suppression on TDF/FTC-containing 3-drug regimens were either switched to TAF/FTC (200/10 mg with b...
Three studies presented at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) explored the pharmacokinetics of antiretrovirals administered during pregnancy. These studies support the use of standard-dose efavirenz, once-daily dolutegravir, and BID ritonavir-boosted darunavir du...
We know that very early treatment in acute HIV infection decreases HIV RNA; this study shows it also greatly decreases proviral DNA (and reservoir size). Researchers investigated 2 small cohorts of patients in Thailand with acute (and very early) HIV infection, 1 untreated and 1 treated with ART ver...
The EMERALD Study is a Phase III, open-label, noninferiority study in which 1,141 patients with stable HIV suppression on a regimen comprising a boosted protease inhibitor plus TDF/FTC were randomized (2:1) to either switch to an investigational single-tablet regimen containing darunavir 800 mg/cobi...
The single-pill combination of bictegravir (BIC) with tenofovir alafenamide (TAF) and emtricitabine (FTC) has been shown in four Phase III trials to be effective as initial therapy.Also as a switch regimen in patients with stably suppressed HIV RNA and no resistance to BIC, TAF, or FTC. In these stu...
Bictegravir (BIC), a new integrase inhibitor, was recently approved by the FDA for use in a single-pill coformulation with TAF/FTC (brand name: Biktarvy) as initial therapy and as a switch regimen for patients who are already on a suppressive ART regimen and who have no history of treatment failure...
Treatment of tuberculosis (TB) in HIV-infected persons remains challenging, in part because of drug interactions between rifampin and some ARVs that may compromise antiretroviral therapy (ART). Three studies presented at CROI provide clinicians with additional guidance on how to manage certain inter...
The U.S. Food and Drug Administration has given approval to a coformulation of darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide (TAF) 10 mg, to be marketed under the brand name Symtuza. DRV/COBI/FTC/TAF constitutes a complete regimen for patients with susceptible HIV, an...
Two pharmacokinetic studies from AIDS 2018 help elucidate the disposition of tenofovir alafenamide (TAF) and cobicistat-boosted darunavir during pregnancy.
The IMPAACT P1026s study examined plasma concentrations of TAF with and without cobicistat in 43 pregnant women. For women taking 25 mg of TAF da...
In April 2019, the U.S. Food and Drug Administration approved a combination pill comprising the integrase inhibitor dolutegravir (DTG), 50 mg, and the NRTI lamivudine (3TC), 300 mg, for use as a complete ARV regimen for initial HIV treatment of patients. The approval specifies that DTG/3TC is intend...
In July 2020, the U.S. Food and Drug Administration approved fostemsavir (FTR) for treatment of people with multi-drug resistant HIV-1 whose current ARV regimen is failing because of resistance, intolerance, or safety issues. FTR is a novel attachment inhibitor that binds the HIV envelope glycoprote...
The AETC Program's new resource combines the most up-to-date, HIV screening, prevention, and care resources in one mobile app, to provide access to essential point-of-care information and expert clinical support with just one touch.
HIV Care Tools is for busy clinicians from novice-to-expert, clinic...
TANGO is a randomized open-label study in which subjects with virologic suppression on standard 3-drug TAF-based ART either switched to the 2-drug regimen of dolutegravir (DTG)/lamivudine (3TC) n = 369) or continued their baseline ART (n = 372). Previously published data showed no significant differ...
The FLAIR study evaluated the efficacy and safety of the long-acting injectable regimen of cabotegravir (CAB) + rilpivirine (RPV) in previously ART-naïve individuals who switched to CAB+RPV after viral suppression on a standard 3-drug oral regimen (dolutegravir [DTG]/ABC/3TC). At both 48 weeks (the...
Imagine: Ending HIV. It’s Possible. is the name of a new, national campaign that launched this summer to encourage and energize the HIV workforce to achieve the national goal of ending the HIV epidemic.
The U.S. Department of Health and Human Services introduced the Ending the HIV Epidemic in the U.S...
Honoring our colleagues who dedicate additional time and resources to research beyond the scope of the AETC Program, we present the updated list of HIV-related peer-reviewed studies published in 2022 by AETC-affiliated researchers and faculty.
If you're aware of other HIV-related peer-reviewed publi...
The FDA recently granted approval to lenacapavir (LEN), a novel long-acting HIV antiretroviral (ARV) that is classified as a capsid inhibitor. Lenacapavir is marketed in the United States as Sunlenca.
Lenacapavir blocks HIV-1’s assembly of its protein capsid and interferes with other steps in HIV rep...
We are pleased to present the updated list of HIV-related peer-reviewed studies published by AETC-affiliated researchers and faculty in 2023.
If you're affiliated with the AETCs and you published an HIV-related peer-reviewed article in 2023 that is not represented here, let us know so we can update t...
